UK biotech firm Summit Therapeutics is preparing a US share offer to raise funding for its research programmes.The Oxford-based company is already listed on London's AIM market, but will now... Read more
Johnson & Johnson has missed out on acquiring its marketing partner Pharmacyclics after AbbVie snatched the company from under its nose with a $21 billion takeover.The acquisition of Pharmacyclics and... Read more
A filing for anti-PD-1 drug Opdivo in lung cancer, plus three new licensing and acquisition deals, shows Bristol-Myers Squibb (BMS) has no intention of slowing its immuno-oncology drive.The US FDA... Read more
Latest Press Releases from the Global Pharma Showcase
World's Largest and Fully Integrated Healthcare Exhibition tHIS announces Further Expansion
The Health Industry Summit, EXPO and Congress (tHIS) held in May in Shanghai announced further increases in size to reach 280,000sqm ahead of its grand opening
The Health Industry Summit (tHIS), already the largest integrated health industry event in the world incorporating the most established Pharmaceutical and Medical events in Asia, has announced inclusion of 2 new shows covering Nutrition and Natural Health - NHNC and the Analytical Testing, Laboratory Equipment - Lab Expo. With the new inclusions and expansions to sold out segments, The organiser Reed Sinopharm have increased the exhibition area from 260,000 sqm to 280,000 sqm. Also, the projected number of professional visitors has been revised up from 150,000 to over 200,000 due to the strength of visitor pre-registration. Undoubtedly, the expansion of tHIS marks the world’s first and largest fully integrated exhibition that brings the entire industrial value chain under one roof and unveils a new chapter in China's massive healthcare industry.
A record breaking 250,000 exhibiting and visiting professionals will descend on Shanghai arriving from 140 countries and all corners of China. While the congregation of so many healthcare professionals is impressive, the gathering of so many high level business travelers will test the capacities of Shanghai’s stared hotels and modern transport system. Meanwhile the newly built show venue, the cutting edge National Convention and Exhibition Center (Shanghai) also gets ready for its first Mega B2B event since construction.
One stop shop for changing business trends
The theme for this very first edition of tHIS is “Convergence”. The 3 main exhibitions within the show, China Medical Equipment Fair (CMEF), PharmChina and the API China were already leading events in their fields, but now with the total of 8 healthcare exhibitions integrated into one mega event, the show will provide an unique one stop solution for the International traders and end buyers with a complete range of products, technology and services that is much more than a convergence of individual exhibitions but reflecting the shifts in the industry.
The vertical and horizontal integration of the healthcare industry is changing in mode and function. The new complete industry value chain comprises the upstream and downstream integration of Active Pharma Ingredients (API), intermediates and preparation sectors as well as the mutual integration of pharmaceuticals and medical devices businesses. This new integrated model of the Chinese healthcare industry is empowering businesses to respond to clinical needs with comprehensive solutions including prevention, diagnosis and treatment of diseases.
New shows extend value chain coverage
Natural health and Nutrition China (NHNC), is the largest exhibition for nutrition in Asia. By joining the mega event and riding on positive policies on product certification, NHNC has now doubled in size to nearly 10,000 sqm this May. Many globally renowned brands have been attracted to NHNC due to its strong synergy with pharmaceutical and commercial resources at PharmChina. For domestic companies in the healthcare business, NHNC has empowered them to expand their market share in the nutrition supplements market.
At the second addition, Test, Laboratory Equipment and Biotech Exhibition (Lab Expo), organised by Sinopharm International Shanghai Co Ltd, visitors will witness exchange of production processes as well as analysis technology for improved pharmaceutical output. Spread over 1,500 sqm within tHIS, this exhibition will feature renowned domestic and international enterprises who will demonstrate products and processes to ensure safety and efficiency of drug development.
Owing to the overwhelming response from global exhibitors and visitors this year, tHIS will be held in Shanghai every spring. Not only will tHIS play an important role in the growth and development of the full-integrated Chinese healthcare industry, it will also inject new vitality into key sectors such as investment policies, research & development (R&D), manufacturing and distribution, clinical practices, educational initiatives and complementary service industries.
About Reed Sinopharm Exhibitions (http://en.reed-sinopharm.com/) Reed Sinopharm Exhibitions ("Reed Sinopharm"/”RSE”) is China’s leading pharmaceutical healthcare exhibition and conference organiser, committed to fostering world-class business events platforms that attract and work with the best pharmaceutical and healthcare enterprises in the industry. With strong roots in both pharmaceutical/healthcare and events management, our vision is to help align industry with favourable government policies and global trends that promise a 'golden age' for China's industry over the coming decades.
A perfect combined expertise, like two best grafted saplings that create a unique and fruitful tree and make the strongest and most resilient partner for businesses with a vision to achieve world-leading status.
Adelphi Research UK Refreshes Corporate Brand & Positioning
Adelphi Research UK has a strong heritage of providing robust market research in the healthcare sector. Established since 2000, they have extensive expertise in pharma, and also span OTC and consumer healthcare, using innovative and digital methods, in both qualitative and quantitative approaches.
Adelphi Research UK’s key proposition has been focused around ‘getting under the skin’ and peeling back the layers, using research expertise and tools to get to the heart of the issue. This proposition has been supported by Adelphi’s impactful red onion branding for the past 6 years.
Changes in market trends and the increased need for robust; quality research that motivates business decisions and drives action has inspired the move towards a refreshed proposition. The new positioning has evolved from a wide consultative process and Adelphi Research UK would like to thank their clients for their valuable input.
Adelphi’s refreshed brand and positioning remains true to their core offering. The new corporate strapline ‘Informing Decisions, Inspiring Action’ accentuates Adelphi’s unique blend of robust market research, with in-house experts that take a consultative approach, to energise brand plans ensuring research lives on for their clients.
Rachel Medcalf, Managing Director, Adelphi Research UK said… “These are exciting times for Adelphi. As the industry continues to evolve, we are well placed with our established experts and innovative toolbox to ensure that insights truly inspire action”.
Adelphi Research UK is part of Adelphi Group, who celebrates 25 years in research this year.
Adelphi Group is a global pharmaceutical consultancy that spans the lifecycle of pharmaceutical development, with comprehensive services in Strategic Product Development Consultancy, Health Economics and Outcomes Research, Real World Disease Understanding, Marketing Research, Medical Communications and Post-meeting Brand Support Services.
Replace the term ‘Key Opinion Leader' say international medical experts
New research reveals pharmaceutical and medical attitudes to ‘KOL’ terminology
Nearly two-thirds (62%) of medical experts believe the pharmaceutical industry should replace the term Key Opinion Leader (KOL)1 – according to the results of a new international survey presented today (27th February) at the Medical Affairs Leaders Forum in Berlin, Germany.
The recommendation follows concerns by the senior medical community (who participated in the research) that the term ‘KOL’ is too ‘closely associated with the world of marketing’ and is often ‘used inappropriately’ for people who do not necessarily warrant the title.
The online survey, which is the first to throw a spotlight on the KOL terminology debate, targeted both senior medical experts and pharmaceutical executives by way of parallel studies. The surveys attracted nearly 400 responses across both the US and Europe.
“Several pharmaceutical companies are now moving away from the term ‘KOL’ as a response to the negative commentary from outside the industry,” says Rosie Bougoffa, outreach and engagement specialist at System Analytic, the company which commissioned the research. “The aim of our survey was to find out if the term ‘KOL’ was now too toxic for everyday use or still the best tool for the job.”
However, despite the negative connotations, when questioned 40% of pharmaceutical executives who participated in the survey opted to keep the name ‘KOL’. This figure compares with just 20% of medical expert respondents in the KOL arm of the study.
“As well as finding out what KOLs and pharmaceutical executives think of the current terminology, we also wanted to ascertain whether the pharmaceutical industry and the medical community should work toward using one universal replacement for the term ‘KOL’?” adds Rosie Bougoffa.
Just over half (56%) of pharmaceutical executives who took part in the survey said that industry should work towards a universal replacement of the term ‘KOL’ – compared to more than three-quarters of medical expert respondents (77%) who stated this should be the case.
The most popular alternative to the term ‘KOL’ among pharmaceutical executives was ‘external expert’, while only 4% of medical respondents appeared to favour this term. Highest scoring alternatives among medical expert participants included ‘therapeutic area expert’ and ‘expert physician’. However, there was an overall lack of consistency on what exactly they thought the replacement term should be – with a total of 24 different options being put forward by the medical expert responders.
Commenting on the results, Dr Rohit Lal, a leading Oncologist at Guy’s Hospital, London, said: “I think that the issue of KOL terminology is important for many reasons and this research shows what people feel about it from both sides. However, whatever term is used in the future, the most important thing is that it acts as a further catalyst to ensure more transparent ways of working across the industry.”
System Analytic will be working with both medical experts and pharmaceutical executives during the coming months to disseminate and gauge opinion on the survey results.
System Analytic helps pharmaceutical teams to identify, map, and engage with their medical experts and key stakeholders. Established in 2007, the company works with world’s leading pharmaceutical companies and the world’s leading physicians to help map the clinical landscape. For more information about System Analytic, visit http://www.systemanalytic.com/
Note to editors: For further information, please contact Lynsey Conway, Aqua Communications, on 07778 304233
References: 1 What’s in name? KOL terminology survey, System Analytic Ltd, 2015
Survey methodology: Field work was undertaken via use of the research tool SurveyGizmo. Questions were a mix of closed and multiple choice questions, with the option to add comments. In total, 185 completed responses were received from pharmaceutical executives across 14 different pharmaceutical companies (including big pharma). 46 percent of pharmaceutical respondents were based in the EU and 36 percent in the US. With regards to KOL and expert respondents, 199 completed responses were analysed in total. System Analytic only surveyed those physicians who could be deemed genuine experts/KOLs and with whom they had previously worked with. All responses from both surveys were completely anonymous.
New Report: Transforming Rare Disease Patients' Lives Through Innovation
Washington, D.C. (February 25, 2015) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
It also explores significant treatment advances seen over the past decade in five rare diseases which have led to improvements in patient survival and quality of life: chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), pulmonary arterial hypertension (PAH), hereditary angioedema (HAE), and cystic fibrosis (CF). Furthermore, the report spotlights additional rare conditions where major milestones transformed treatment —including several in which first-ever treatment options have become available to patients.
Key findings include:
Targeted therapies can now effectively treat many of the recently identified mutated forms of CML and allow for treatment plans tailored to each patient’s particular genetic profile.
Novel targeted therapies treat the root cause of CLL, resulting in lasting remissions and new treatment options for even the sickest patients.
New treatments go beyond symptom management to treat the underlying cause of PAH, allowing patients to maintain active lifestyles with reduced risk of serious heart events.
New discoveries in the underlying cause of HAE have led to breakthroughs in both preventative and acute treatment options for patients, including those targeting the root cause of the disease.
CF patients now have new treatment options allowing for better management of symptoms as well as a new option which allows many to target the underlying cause of their disease. If mortality rates continue to decline, patients may now hope to live into their 50s
“Rare diseases are one of the most scientifically complex health challenges we face,” said PhRMA President and CEO John J. Castellani. “Over the last 10 years, biopharmaceutical researchers have leveraged cutting-edge technologies and dramatically expanded our understanding of rare diseases to develop new therapies for chronic myelogenous leukemia, cystic fibrosis, and other diseases which often impact very small patient populations. We continue to work toward options for rare disease patients, where there may currently be few or no treatments available.”
The new report was released ahead of Rare Disease Day, which will be celebrated on Saturday, February 28, 2015. The day is an opportunity for the international rare disease community – including academia, patient advocacy groups, pharmaceutical and biotechnology companies, research and regulatory government agencies – to collectively educate and raise awareness about rare diseases and their impact on the lives of patients and their families.
Thirty million Americans, or one in ten, and an estimated 350 million people worldwide are currently living with a rare disease, which is defined as a condition that affects fewer than 200,000 people. There are currently 7,000 known rare diseases and approximately 80 percent are caused by genetic abnormalities. However, despite incredible progress made against rare disease in recent years, only 5 percent have available treatment options.
While there remains a significant need to develop new medicines for patients, this is a challenging endeavor. Rare diseases are often complex and the underlying biological mechanisms that cause them are not always well understood. Nevertheless, researchers continue to build on recent breakthroughs and are dedicated to bringing new medicines to patients. With more than 450 medicines in development to treat rare disease, the promise has never been greater for patients.
To view the full “A Decade of Innovation in Rare Diseases” report, click here.